Naslov
Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma

Autori
Škopljanac, Ivan ; Šegrt, Ivana ; Miše, Kornelija ; Vukovac, Emilija Lozo ; Biočina, Anita Tolić

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
EUROPEAN RESPIRATORY JOURNAL / - , 2018

Skup
28th International Congress of the European Respiratory Society (ERS 2018)

Mjesto i datum
Pariz, Francuska, 15.09.2018. - 19.09.2018

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
malignant pleural mesothelioma ; cisplatin ; pemetrexed ; chemotherapy ; palliative care ; survival

Sažetak
Introduction: Malignant pleural mesothelioma is a rare tumour commonly associated with asbestos exposure however with increasing incidence and poor survival. The standard first-line chemotherapy regimen is the combination of cisplatin and pemetrexed, with median overall survival of ̴ 13 months. Other therapeutic options like surgery, radiation and immunotherapy are currently limited therefore patient's performance status and histological subtype are the only prognostic factors (Scherpereel A. et al. EurRespir J 2010 ; 35: 479-95, Scherpereel A. EurRespir J.2017 Mar 15 ; 49(3). Aim and Objectives: The aim of study was to compare the patient's survival depending on whether they received chemotherapy or not. Methods: We identified retrospectively 24 patients diagnosed with pleural mesothelioma in Department of Pulmonology, Clinical Hospital Center Split, Croatia evaluating their management, whether they were treated by cisplatin/pemetrexed or solely palliative care as a result of poor performance status or refusal of any specific treatment. Kaplan-Meier survival analysis was used (MedCalc Software ver. 18). Results: The overall median survival (OS) time was 14, 6 months. A pronounced OS benefit for palliative care versus cisplatin/pemetrexed was observed, 17 vs 8 months, respectively ; HR, 0, 3665 ; 95% CI, 0, 14 to 0, 90 ; P = 0, 0047, Fig. 1. Conclusions: Chemotherapeutic treatment did not show better outcomes than solely palliative treatment. Future prospective randomized controlled studies are necessary to optimize the treatment of malignant mesothelioma.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA